Skip to main content
Xiaobu Ye on Muck Rack

Xiaobu Ye

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Xiaobu

Contact Xiaobu, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial

|
By Michael Lim, Arati Desai, Manmeet Ahluwalia, Tobias Walbert, Glenn J. Lesser, Benjamin M. Ellingson, David Peereboom, Joy Fisher, Christina Jackson, Ayush Pant, Aanchal Jain, Rohit Verma, Benjamin Oberlton, Hadeesha Piyadasa, Chetan Bettegowda, Logan Engle, Janis Taube, Sean C. Bendall, John Choi, Jan Drappatz, Frank Lieberman, Lawrence Kleinberg, Drew Pardoll, Louis B. Nabors, Patrick Y Wen, Stuart A Grossman, Xiaobu Ye, Anna F. Piotrowski, Serena Desideri
| Nature Verified
Abstract Lymphocyte activation gene 3 (LAG-3) is an immune checkpoint implicated in T cell exhaustion and a potential therapeutic target in glioblastoma (GBM). We conducted a multicenter, open-label, phase 1 study with sequential allocation to evaluate the safety and preliminary activity of the anti-LAG-3 antibody relatlimab, administered alone or with the anti-programmed cell death protein 1 (PD-1) antibody nivolumab, in patients with recurrent GBM.
Open in Who Shared Issue with article?
See all 1 articles